Markets:

Overview

News

Currencies

International

Treasuries

Astrazeneca Plc Ord (OP:AZNCF)

186.40 UNCHANGED

Streaming Delayed Price Updated: 11:09 AM EST, Dec 24, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Astrazeneca Plc Ord

< Previous 1 2 3 4 5 6 7 8 9 Next >

5 Oversold Stocks to Buy Right Now

September 16, 2024

We've got you covered with a list of oversold stocks to buy right now. Learn more about oversold and overbought stocks on MarketBeat.

Via MarketBeat

3 stocks that crushed earnings estimates and still tanked

November 20, 2023

Every earnings season, regardless of sector or industry, has its share of stocks that go down even after beating earnings expectations such as these stocks

Via MarketBeat

AstraZeneca Abandons Blood Cancer, Cardiovascular Programs Amid Portfolio Prioritization ↗

July 28, 2023

Earlier today, AstraZeneca plc (NASDAQ: AZN)

Via Benzinga

AstraZeneca Q2 Earnings Beat Consensus Despite Zero COVID-19 Vaccine Sales, Stock Shoots Up ↗

July 28, 2023

AstraZeneca Plc's (NASDAQ: AZN) unit Alexion has

Via Benzinga

AstraZeneca-Sanofi's Respiratory Syncytial Virus Treatment Scores FDA Approval To Prevent Infection In Infants ↗

July 18, 2023

The FDA approved AstraZeneca Plc (NASDAQ:

Via Benzinga

AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial ↗

July 03, 2023

AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...

Via Benzinga

AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer ↗

June 29, 2023

AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)...

Via Benzinga

AstraZeneca Seeks Expanded Use For Soliris As First Targeted Therapy For Pediatric Patients With Autoimmune Neuromuscular Disease ↗

June 26, 2023

The European Union has reco

Via Benzinga

Why Are Pieris Pharmaceuticals Shares Tanking Today ↗

June 21, 2023

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) announced that partner AstraZeneca plc (NASDAQ: AZN) decided to discontinue and cease dosing in the ongoing clinical studies of elarekibep, an inhaled IL-4...

Via Benzinga

AstraZeneca Mulls China Business Unit Spin-Off Amid Geopolitical Tensions ↗

June 20, 2023

European drugmaker AstraZeneca plc (NASDAQ: AZN) is reportedly drafting a plan to spin off its China business, and listing a separate unit in Hong Kong is considered an option amid mounting...

Via Benzinga

AstraZeneca's Add On Treatment With Standard Care Improves Hemoglobin Levels In Rare Blood Disorder ↗

June 09, 2023

AstraZeneca Plc (NASDAQ: AZN)

Via Benzinga

AstraZeneca Inks Over $2B Agreement For Cell Therapies Targeting Diabetes ↗

June 09, 2023

AstraZeneca plc (NASDAQ: AZN) has entered into a

Via Benzinga

Unanimous Support for AstraZeneca and Sanofi's Nirsevimab: Next Generation RSV Treatment on the Horizon ↗

June 09, 2023

The FDA's Antimicrobial Drugs Advisory Committee has voted unanimously 21 to 0 that AstraZeneca plc (NASDAQ: AZN) and Sanofi SA's (NASDAQ: SNY) nirsevimab has a favorable benefit-risk profile t

Via Benzinga

AstraZeneca's Tagrisso Significantly Enhances Survival in Certain Post Surgery Non-Small Cell Lung Cancer Patients ↗

June 05, 2023

Via Benzinga

AstraZeneca/Merck's Cancer Drug Combo Shows Positive Results In Endometrial Cancer ↗

May 26, 2023

Via Benzinga

AstraZeneca's China Executive Seeks Loyalty to "Love the Communist Party" In China ↗

May 19, 2023

During an event held in the city of Wuxi to commemorate its 30th year in China, AstraZeneca Plc's (NASDAQ: AZN) China president, Wang Lei, said the company will seek to be a patriotic company in China...

Via Benzinga

One More Quits US Pharma Lobby Group: AstraZeneca Follows Teva, AbbVie Footsteps ↗

May 17, 2023

AstraZeneca Plc (NASDAQ: AZN) has decided to leave a U.S. drug lobby group, the Pharmaceutical Research and Manufacturers of America (PhRMA), making it the third company to leave the group in the last...

Via Benzinga

AstraZeneca' Tagrisso/Chemo Combo Therapy Delays Treatment Resistance, Disease Progression In Certain Type Of Advanced Lung Cancer ↗

May 17, 2023

AstraZeneca Plc (NASDAQ: AZN) has reported topline data

Via Benzinga

Sanofi, AstraZeneca Release Real-World Data For Respiratory Syncytial Virus Antibody ↗

May 12, 2023

The race to tap the respiratory syncytial virus (RSV) this season intensifies as Sanofi SA (NASDAQ: SNY) and AstraZeneca Plc (NASDAQ: AZN) have

Via Benzinga

FDA Advisory Committee Votes Favoring Restricted Use Of AstraZeneca/Merck's Prostate Cancer Drug ↗

May 01, 2023

Via Benzinga

FDA Casts Doubt on Merck/AstraZeneca's Cancer Drug for Prostate Cancer Ahead of Adcomm Meeting ↗

April 27, 2023

The FDA's Oncologic Drugs Advisory Committee will be meeting tomorrow, Friday, 28 April, to discuss the supplemental new drug application (sNDA) for Lynparza (olaparib) in combination with abiraterone...

Via Benzinga

AstraZeneca's COVID-19 Vaccine Loses Shine, Cancer Drug Imfinzi & Emerging Markets Stabilize Q1 Revenues ↗

April 27, 2023

AstraZeneca Plc (NASDAQ: AZN) has reported Q1 FY23 core EPS of $1.92, up 1% Y/Y (+6% on constant currency), better than the consensus of $1.07. The company clocked Q1 sales of $10.88 billion, -4% (flat...

Via Benzinga

AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression ↗

April 24, 2023

Via Benzinga

Why AstraZeneca Shares Are Trading Higher Today? ↗

April 18, 2023

AstraZeneca plc's (NASDAQ: AZN) vaccine head highlighted the confidence that the company's new COVID-19 antibody treatment could protect immunocompromised patients against all known virus variants.

Via Benzinga

Canadian Cancer Diagnostic Company BioMark Working On Early Lung Detection Assay ↗

April 10, 2023

Via Benzinga

AstraZeneca' Cancer Drug Combo Meets Goal In Late-Stage Ovarian Cancer Study ↗

April 05, 2023

Via Benzinga

Pieris Pharma Pushes Elarekibep Data Readout, Investors React Negatively ↗

March 29, 2023

Via Benzinga

AstraZeneca Axes Pneumonia Drug Pact With Aridis ↗

March 29, 2023

AstraZeneca plc (NASDAQ: AZN) scrapped its license agreement with Aridis Pharmaceuticals Inc (NASDAQ: ARDS).

Via Benzinga

AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review ↗

March 27, 2023

Via Benzinga

AstraZenceca's Tagrisso Shows Survival Benefit In Early-Stage Lung Cancer Settings ↗

March 09, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Astrazeneca Plc Ord (OP:AZNCF)

All News about Astrazeneca Plc Ord

Starting at $3.75/week.

Subscribe Today